GlobeNewsWire - Biofrontera (B8F) Biofrontera reports Q1 2020 financial results

Almost there...

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

First Name*

Last Name*

Country*

Email*

Password* ( 6 or more alphabetic and numerical characters )

Get financial insights straight to your inbox

YES

I have read and accept ResearchPool Terms & Conditions, and Privacy Policy, including our Cookie Use Policy

Already on ResearchPool? Login Now

B8F Biofrontera

Biofrontera reports Q1 2020 financial results

Leverkusen, May 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2020 and provided an update on recent developments.

Key financial figures and business performance in Q1 2020

EUR thousands	3M 2020	3M 2019	Change
Total revenue	6,473	6,808	(5%)
Research and development costs	(1,311)	(1,088)	21%
General administrative costs	(2,232)	(1,974)	13%
Sales costs	(8,698)	(5,554)	57

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

B8F Biofrontera

Biofrontera reports Q1 2020 financial results

Biofrontera reports Q1 2020 financial results